Empagliflozin/linagliptin/metformin - Boehringer Ingelheim / Eli Lilly and Company

Drug Profile

Empagliflozin/linagliptin/metformin - Boehringer Ingelheim / Eli Lilly and Company

Alternative Names: Empagliflozin/linagliptin/metformin extended release; Empagliflozin/linagliptin/metformin XR

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim; Eli Lilly
  • Class Antihyperglycaemics
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Diabetes mellitus

Most Recent Events

  • 13 Nov 2017 Boehringer Ingelheim and Eli Lilly completes a phase I trial in Healthy volunteers in Germany (PO) (NCT03259490)
  • 31 Aug 2017 Boehringer Ingelheim initiates enrolment in a phase I trial in Healthy volunteers in Germany (PO) (NCT03259490)
  • 30 Aug 2017 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Germany (NCT03259490)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top